Opsona Therapeutics is a leading drug development company specialising in the human immune system.
Opsona is identifying new ways to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases.
Opsona's drug discovery & development is focused on the role of Toll-Like Receptors (TLRs) and Inflammasome signalling in human immunology. Since 2004, Opsona has also developed a unique and advanced pipeline of drugs. The company has research locations in Dublin (Ireland) and Lausanne (Switzerland).
Opsona is identifying new ways to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases.
Opsona's drug discovery & development is focused on the role of Toll-Like Receptors (TLRs) and Inflammasome signalling in human immunology. Since 2004, Opsona has also developed a unique and advanced pipeline of drugs. The company has research locations in Dublin (Ireland) and Lausanne (Switzerland).
Location: Ireland, Dublin City, Dublin
Employees: 11-50
Total raised: $47.29M
Founded date: 2004
Investors 2
| Date | Name | Website |
| - | Inventages | inventages... |
| - | Fountain H... | fh-partner... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 02.10.2013 | Series C | $4.07M | - |
| 29.04.2013 | Series C | $43.22M | - |
Mentions in press and media 7
| Date | Title | Description |
| 12.09.2016 | Dublin Medical Startup Inflazome Raises €15m | Dublin startup Inflazome, which was formed in April of this year, has raised €15m to help it develop treatments for chronic inflammatory diseases. The substantial funding round was co-led by life science VC firms Novartis Venture Funds and ... |
| 09.01.2015 | Irish VC Fountain Healthcare launches $127.5M fund | –Chrono Therapeutics, a Bay Area digital smoking cessation startup –Innocoll, an Irish maker of biodegradable surgical implants and topical adhesives to treat post-op pain and diabetic foot ulcers. Its previous investments include: –Civitas... |
| 02.10.2013 | Opsona Adds 3M EURO To Series C Round | DUBLIN, IRELAND, Opsona Therapeutics Limited, a drug development company, has added 3 million euro from Omnes Capital to a Series C financing round that now totals 36 million euro. >> Click here for more funding data on Opsona Ther... |
| 02.10.2013 | Opsona Therapeutics Raises €3M Series C Equity Financing | Opsona Therapeutics Limited, a Dublin, Ireland-based innate immune drug development company, raised €3m (US$4m) in a second closing of its Series C equity financing. New investor Omnes Capital provided the funding, which brings the total ra... |
| 29.04.2013 | Opsona Therapeutics $43M Series C | DUBLIN, IRELAND, Innate immune drug development company, today announced that it has raised EURO33 million (US $ 43 million) in an oversubscribed Series C financing. >> Click here for more funding data on Opsona Therapeutics >&... |
| 29.04.2013 | Opsona Therapeutics Raises €33M in Series C Financing | Opsona Therapeutics, a Dublin, Ireland-based developer of new treatments for inflammatory diseases, raised €33m (US$43m) in Series C financing. The round was led by BB Biotech Ventures and Novartis Venture Fund, with participation from new ... |
| - | Irish VC Fountain Healthcare launches $127.5M fund | Fountain Healthcare Partners just closed its second fund, with €85 million – or about $127.5 million. The Irish VC firm – which has offices in New York – plans to make 10 to 15 investments in the fields of specialty pharma, biotech, medical... |